Answers are grounded in this paper and cite their sources.
Case studies demonstrate targeted therapy led to tumor size reduction in pediatric high-grade astrocytoma with NTRK fusion, highlighting diagnostic complexities.
HGAP is a newly described, rare glial neoplasm within the realm of pediatric neuro-oncology. Characterized by pathognomonic epigenetic signatures, HGAP poses diagnostic challenges due to histological similarities with more common entities, such as pilocytic astrocytoma. These overlapping features create high risk for misdiagnosis resulting inadequate treatment leading to poor outcomes for such aggressive tumors. Comprehensive literature review reveals less than 20 pediatric cases, with only one reporting an NTRK fusion. Herein, we present the case of an 11-year-old male with HGAP. The patient presented with poor weight gain, bilateral sensorineural hearing loss, marked ataxia, and nystagmus. MRI revealed a large dorsally exophytic, heterogeneously enhancing solid/cystic lesion at the cervicomedullary junction, extending into the 4th ventricle with associated hydrocephalus but no diffusion restriction or metastatic disease. Following subtotal resection, histopathological findings were consistent with a biphasic pilocytic astrocytoma showing abundant Rosenthal fibers, vascular sclerosis. Notably there were no obvious mitoses, low Ki67 index with ATRX mostly retained. Surprisingly, molecular testing with methylation demonstrated high confidence score for HGAP. Paired tumor-normal exome sequencing revealed no germline alterations, with somatic CDKN2A/2B biallelic loss, missense variant and copy number loss involving NF1 with loss of function splice variant in ATRX. Solid tumor fusion panel revealed a BCR::NTRK2 fusion. Postoperatively, the patient developed left-sided hemiparesis, right-sided facial nerve, and vocal cord palsy. He received therapy with focal photon radiation followed by 12 cycles of Larotrectinib, showing a remarkable radiological response with sustained reduction in tumor size and volume, and full functional recovery. Unfortunately, surveillance imaging four months after therapy revealed local recurrence. Given his excellent initial response and tolerance with no dose limiting toxicity, Larotrectinib was restarted.This case highlights the critical importance of molecularly guided diagnostic workups and underscores the potential of targeted therapies like Larotrectinib in managing rare entities such as HGAP.
No takes yet. Share an insight, caveat, or question.
Brandt et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: